undamentalytics Newsletter
Sign in

Exelixis, Inc. cash flow statement

In fiscal 2025, Exelixis, Inc.'s operations generated $884m of cash; it spent $8.4m on capital projects, leaving free cash flow of $876m. It returned $948m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Jan 20162016Dec 20162017Dec 20172018Dec 20182019Jan 20202020Jan 20212021Dec 20212022Dec 20222023Dec 20232024Jan 20252025Jan 2026LTMOct 2026
Cash from operations−15−101−159−123−199−235−1412101664165272094013633337008841,173
Depreciation and amortisation13117632111589142126292928
Stock-based pay23211291210222324415710512010810694113110
Capital spending621320022133133054284028812
Free cash flow−20−103−160−126−201−236−1412091443825141793473352936728761,161
Free cash flow after stock pay−43−124−172−135−213−246−163186121342458742272271875787631,051
Share buybacks————————————005506529481,261
Shares issued—017920307614600—————————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: EXEL vs NTRAEXEL vs MRNAEXEL vs UTHR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Exelixis, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Exelixis, Inc.